Long-term outcome and its predictors in giant cell myocarditis

European Journal of Heart Failure

Volumn 18, Issue 12, 2016, Pages 1452-1458

  Ekström, Kaj ^a   Lehtonen, Jukka ^a   Kandolin, Riina ^a   Räisänen Sokolowski, Anne ^a   Salmenkivi, Kaisa ^a   Kupari, Markku ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Inflammatory cardiomyopathy; Myocardial biopsy; Transplantation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; OKT 3; PREDNISONE; TACROLIMUS; TROPONIN T; ANTIARRHYTHMIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; CLINICAL ARTICLE; DISEASE SEVERITY; EVENT FREE SURVIVAL; EXTRACORPOREAL OXYGENATION; FEMALE; GIANT CELL MYOCARDITIS; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR ASSIST DEVICE; MALE; MORTALITY; MYOCARDITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; ATRIOVENTRICULAR BLOCK; CARDIAC MUSCLE; COMPLICATION; HEART FAILURE; HEART PACING; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AMIODARONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ATRIOVENTRICULAR BLOCK; CARDIAC PACING, ARTIFICIAL; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDITIS; MYOCARDIUM; PACEMAKER, ARTIFICIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 84978811114     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.606     Document Type: Article

References (17)

1. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis—natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997;336:1860–1866.
2. Okura Y, Dec GW, Hare JM, Kodama M, Berry GJ, Tazelaar HD, Bailey KR, Cooper LT. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 2003;41:322–329.
3. Cooper LT Jr, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, Menon S, Mullen GM, Jaski B, Bailey KR, Cunningham MW, Dec GW. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008;102:1535–1539.
4. Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss HP, Cooper LT. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol 2015;115;1733–1738.
5. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013;6:15–22.
6. Larsen BT, Maleszewski JJ, Edwards WD, Cooper LT Jr, Sobonya RE, Thompson VE, Duckett SG, Peebles CR, Simpson IA, Tazelaar HD. Atrial giant cell myocarditis: a distinctive clinicopathologic entity. Circulation 2013;127:39–47.
7. Ren H, Poston RS Jr, Hruban RH, Baumgartner WA, Baughman KL, Hutchins GM. Long survival with giant cell myocarditis. Mod Pathol 1993;6:402–407.
8. Davies RA, Veinot JP, Smith S, Struthers C, Hendry P, Masters R. Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome. J Heart Lung Transplant 2002;21:674–679.
9. Kandolin R, Lehtonen J, Graner M, Schildt J, Salmenkivi K, Kivistö SM, Kupari M. Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011;270:461–468.
10. Saenger AK, Beyrau R, Braun S, Cooray R, Dolci A, Freidank H, Giannitsis E, Gustafson S, Handy B, Katus H, Melanson SE, Panteghini M, Venge P, Zorn M, Jarolim P, Bruton D, Jarausch J, Jaffe AS. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta 2011;412:748–754.
11. Cooper LT Jr, Okura Y. Idiopathic giant cell myocarditis. Curr Treat Options Cardiovasc Med 2001;3:463–467.
12. Litovsky SH, Burke AP, Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 1996;9:1126–1134.
13. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250–262.
14. Menghini VV, Savcenko V, Olson LJ, Tazelaar HD, Dec GW, Kao A, Cooper LT Jr. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc 1999;74:1221–1226.
15. Suarez-Barrientos A, Wong J, Bell A, Lyster H, Karagiannis G, Banner NR. Usefulness of rabbit anti-thymocyte globulin in patients with giant cell myocarditis. Am J Cardiol 2015;116:447–451.
16. Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H, Amaki M, Kanzaki H, Okamura H, Kamakura S, Shimizu W, Anzai T, Kitakaze M. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in left ventricular function after steroid therapy in cardiac sarcoidosis. Heart 2014;100:1165–1172.
17. Vittinghoff E, McCulloh CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007;165:710–718.